TY - JOUR
T1 - Lobular neoplasia of the breast revisited with emphasis on the role of e-cadherin immunohistochemistry
AU - Dabbs, David J.
AU - Schnitt, Stuart J.
AU - Geyer, Felipe C.
AU - Weigelt, Britta
AU - Baehner, Frederick L.
AU - Decker, Thomas
AU - Eusebi, Vincenzo
AU - Fox, Stephen B.
AU - Ichihara, Shu
AU - Lakhani, Sunil R.
AU - Palacios, Jose
AU - Rakha, Emad
AU - Richardson, Andrea L.
AU - Schmitt, Fernando C.
AU - Tan, Puay Hoon
AU - Tse, Gary M.
AU - Vincent-Salomon, Anne
AU - Ellis, Ian O.
AU - Badve, Sunil
AU - Reis-Filho, Jorge S.
N1 - Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2013/7
Y1 - 2013/7
N2 - Lobular neoplasia (LN) is a term that encompasses both lobular carcinoma in situ and atypical lobular hyperplasia. These lesions have been shown to constitute both risk indicators and nonobligate precursors of invasive breast cancer, they are relatively uncommon, and are most often identified in specimens taken for other reasons. Their incidence has increased in the last 2 decades, and novel variants, including a pleomorphic type, have been described. Loss of E-cadherin expression is recognized as a hallmark diagnostic feature of LN and invasive lobular carcinomas, and immunohistochemical (IHC) analysis using anti-E-cadherin antibodies has been proven to be a useful method to differentiate between lobular and ductal lesions. The frequent use of E-cadherin IHC analysis in routine diagnostic histopathology, however, has resulted in confusion with regard to the actual value of IHC with antibodies against E-cadherin and other proteins of the cadherincatenin complex. This review provides an update on recent clinicopathologic and molecular data on LN and invasive lobular carcinoma and a discussion about the use and limitations of IHC with E-cadherin in diagnostic breast pathology.
AB - Lobular neoplasia (LN) is a term that encompasses both lobular carcinoma in situ and atypical lobular hyperplasia. These lesions have been shown to constitute both risk indicators and nonobligate precursors of invasive breast cancer, they are relatively uncommon, and are most often identified in specimens taken for other reasons. Their incidence has increased in the last 2 decades, and novel variants, including a pleomorphic type, have been described. Loss of E-cadherin expression is recognized as a hallmark diagnostic feature of LN and invasive lobular carcinomas, and immunohistochemical (IHC) analysis using anti-E-cadherin antibodies has been proven to be a useful method to differentiate between lobular and ductal lesions. The frequent use of E-cadherin IHC analysis in routine diagnostic histopathology, however, has resulted in confusion with regard to the actual value of IHC with antibodies against E-cadherin and other proteins of the cadherincatenin complex. This review provides an update on recent clinicopathologic and molecular data on LN and invasive lobular carcinoma and a discussion about the use and limitations of IHC with E-cadherin in diagnostic breast pathology.
KW - Atypical lobular hyperplasia
KW - Comparative genomic hybridization
KW - Gene expression profiling
KW - Immunohistochemistry
KW - Invasive lobular carcinoma
KW - Lobular carcinoma in situ
KW - Lobular neoplasia
KW - Pleomorphic lobular carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84880317363&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880317363&partnerID=8YFLogxK
U2 - 10.1097/PAS.0b013e3182918a2b
DO - 10.1097/PAS.0b013e3182918a2b
M3 - Article
C2 - 23759937
AN - SCOPUS:84880317363
VL - 37
SP - e1-e11
JO - American Journal of Surgical Pathology
JF - American Journal of Surgical Pathology
SN - 0147-5185
IS - 7
ER -